|
|
News Breaks | | | | January 25, 2013 | | 09:02 EDT |  | SGEN | Seattle Genetics presents data from ASG-5ME Phase I trial
Seattle Genetics presented interim results from a phase I clinical trial evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma at the American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium being held January 24-26, 2013 in San Francisco, CA. ASG-5ME is an antibody-drug conjugate targeting the SLC44A4 antigen and is being co-developed by Seattle Genetics and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of solid tumors. The phase I data from the ASG-5ME clinical trial in advanced pancreatic cancer identified the maximum tolerated dose for weekly administration, demonstrated tolerability and provided preliminary evidence for antitumor activity. Enrollment of PDA patients to this ASG-5ME phase I trial is complete. | |
|
News For SGEN From The Last 14 Days Check below for free stories on SGEN the last two weeks. |
|
|
| June 19, 2013 | | 09:05 EDT | | SGEN | Seattle Genetics, Takeda announce data from analysis of PFS with ADCETRIS
Takeda Pharmaceutical and Seattle Genetics announced data from a post-hoc analysis examining progression-free survival, PFS, following treatment with ADCETRIS versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma post-autologous stem cell transplant or relapsed or refractory systemic anaplastic large cell lymphoma. The data were highlighted during a presentation at the 12th International Conference on Malignant Lymphoma being held June 19–22, 2013 in Lugano, Switzerland. The post-hoc analysis compared investigator assessed PFS following ADCETRIS single-agent treatment to the last prior systemic therapy in patients taking part in two pivotal Phase 2 studies. “These encouraging data suggest that ADCETRIS may delay disease progression compared to prior therapies used in this heavily pretreated patient population,” said John Radford, M.D., Professor of Medical Oncology, University of Manchester, Manchester, UK. “ADCETRIS is a CD30-targeted treatment option for patients with relapsed or refractory HL or relapsed or refractory sALCL that has shown a high overall response rate, including durable complete responses in both of its approved indications.” | | | June 10, 2013 | | 09:19 EDT | | SGEN | Seattle Genetics announces start of Hodgkin Lymphoma treatment phase 1/2 trial
Seattle Genetics announced the initiation of a phase 1/2 clinical trial evaluating Adcentris in combination with bendamustine for patients with Hodgkin lymphoma after first relapse. The multi-phase study is divided into two cohorts to determine the recommended dosing level and tolerability of combination use and to assess the complete remission rate associated with Adcentris in combination with bendamustine. Of the 14 evaluable patients, 12 patients had an objective response rate, including seven complete remissions and five partial remissions. The most common Grade 1 or 2 adverse events were peripheral sensory neuropathy, acneiform rash, AST elevation, and fatigue. Grade 3 adverse events were rash acneiform and urinary tract infection and there were no Grade 4 adverse events. | | | 07:40 EDT |  | SGEN | Leerink's biotech analyst holds analyst/industry conference call on ASCO
 Subscribe for More Information | |
|
|
|
|
|
|
